Fluoropolymer-coated Dacron versus PTFE grafts for femorofemoral crossover bypass:: Randomised trial

被引:27
作者
Eiberg, J. P.
Roder, O.
Stahl-Madsen, M.
Eldrup, N.
Qvarfordt, P.
Laursen, A.
Greve, M.
Floerenes, T.
Nielsen, O. M.
Seidelin, C.
Vestergaard-Andersen, T.
Schroeder, T. V.
机构
[1] Rigshosp, Dept Vasc Surg, DK-2100 Copenhagen, Denmark
[2] Dept Vasc Surg, Odense, Denmark
[3] Dept Vasc Surg, Kolding, Denmark
[4] Dept Surg, Helsingborg, Sweden
[5] Dept Vasc Surg, Skejby, Denmark
[6] Dept Surg, Slagelse, Denmark
[7] Dept Surg, Oslo, Norway
[8] Dept Surg, Hillerod, Denmark
[9] Dept Vasc Surg, Gentofte, Denmark
[10] Dept Vasc Surg, Viborg, Denmark
关键词
femorofemoral bypass; patency; fluoropassivated Dacron; PTFE;
D O I
10.1016/j.ejvs.2006.04.018
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objectives. To investigate whether patency of a thin walled 8 mm fluoropassivated Dacron graft was similar to that of a standard 8 mm PTFE graft for femorofemoral crossover bypass surgery. Design. A randomised multicentre clinical trial comparing two vascular grafts with participation of 10 departments of vascular surgery in Denmark, Sweden and Norway. Patients and methods. 198 patients were randomised to PTFE (n =107) or fuoropolymer-coated Dacron grafts (n=91), 63% underwent surgery for claudication, 27% for ischaemic rest pain and 10% for tissue loss. The median follow-up time was 24 months (IQR 19-26 months). Results. The primary patency rate of the two grafts was similar (log rank test: p = 0.35). The primary patency rates (95% CI) for coated Dacron and PTFE grafts were 92% (86-98) and 94% (89-99) at 12 months and 87% (74-95) and 93% (87-99) at 24 months, respectively. Conclusion. In patients with unilateral iliac artery disease not amenable to angioplasty, the femoral femoral bypass is durable and effective. No difference in patency was found between the two graft materials (fluoropolymer coated Dacron and PTFE).
引用
收藏
页码:431 / 438
页数:8
相关论文
共 29 条
[1]   Prosthetic above-knee femoropopliteal bypass grafting: Results of a multicenter randomized prospective trial [J].
Abbott, WM ;
Green, RM ;
Matsumoto, T ;
Wheeler, JR ;
Miller, N ;
Veith, FJ ;
Suggs, WD ;
Hollier, L ;
Money, S ;
Garrett, HE ;
Moore, WS ;
Dean, RH ;
Cronenwett, JL ;
Carter, S ;
Greenhalgh, RM ;
ODonnell, TF .
JOURNAL OF VASCULAR SURGERY, 1997, 25 (01) :19-28
[2]   Development of intimal hyperplasia in six different vascular prostheses [J].
Ao, PY ;
Hawthorne, WJ ;
Vicaretti, M ;
Fletcher, JP .
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2000, 20 (03) :241-249
[3]   EFFICACY OF FEMOROFEMORAL BYPASS FOR INTERMITTENT CLAUDICATION - CLINICAL AND HEMODYNAMIC ASSESSMENT [J].
BUCHBINDER, D ;
PASCH, AR ;
SCHULER, JJ ;
MEYER, JP ;
DILLON, BC ;
ROLLINS, DL ;
FLANIGAN, DP .
AMERICAN JOURNAL OF SURGERY, 1986, 152 (02) :215-219
[4]   A CLINICAL SURVEY OF AORTOBIFEMORAL BYPASS USING 2 INHERENTLY DIFFERENT GRAFT TYPES [J].
CINTORA, I ;
PEARCE, DE ;
CANNON, JA .
ANNALS OF SURGERY, 1988, 208 (05) :625-630
[5]   FEMOROFEMORAL BYPASS GRAFT - ANALYSIS OF PATENCY AND FACTORS INFLUENCING LONG-TERM OUTCOME [J].
CRIADO, E ;
BURNHAM, SJ ;
TINSLEY, EA ;
JOHNSON, G ;
KEAGY, BA ;
KERSTEIN, MD ;
ABURAHMA, AF .
JOURNAL OF VASCULAR SURGERY, 1993, 18 (03) :495-505
[6]   Heparin-bonded Dacron or polytetrafluorethylene for femoropopliteal bypass: Five-year results of a prospective randomized multicenter clinical trial [J].
Devine, C ;
McCollum, C .
JOURNAL OF VASCULAR SURGERY, 2004, 40 (05) :924-931
[7]  
HARRIS JM, 1987, ANN SURG, V206, P612
[8]  
HARRIS JP, 1981, SURGERY, V90, P764
[9]   Durability of femorofemoral bypass grafting after aortouniiliac endovascular aneurysm repair [J].
Hinchliffe, RJ ;
Alric, P ;
Wenham, PW ;
Hopkinson, BR .
JOURNAL OF VASCULAR SURGERY, 2003, 38 (03) :498-503
[10]   Comparative evaluation of externally supported Dacron and polytetrafluoroethylene prosthetic bypasses for femorofemoral and axillofemoral arterial reconstructions [J].
Johnson, WC ;
Lee, KK .
JOURNAL OF VASCULAR SURGERY, 1999, 30 (06) :1077-1083